GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Current Ratio

Mural Oncology (Mural Oncology) Current Ratio : 11.27 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mural Oncology's current ratio for the quarter that ended in Mar. 2024 was 11.27.

Mural Oncology has a current ratio of 11.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Mural Oncology's Current Ratio or its related term are showing as below:

MURA' s Current Ratio Range Over the Past 10 Years
Min: 0.12   Med: 4.88   Max: 47.33
Current: 11.27

During the past 3 years, Mural Oncology's highest Current Ratio was 47.33. The lowest was 0.12. And the median was 4.88.

MURA's Current Ratio is ranked better than
82.17% of 1542 companies
in the Biotechnology industry
Industry Median: 3.77 vs MURA: 11.27

Mural Oncology Current Ratio Historical Data

The historical data trend for Mural Oncology's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Current Ratio Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Current Ratio
0.13 0.12 9.56

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only - 47.33 0.19 9.56 11.27

Competitive Comparison of Mural Oncology's Current Ratio

For the Biotechnology subindustry, Mural Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Current Ratio distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Current Ratio falls into.



Mural Oncology Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Mural Oncology's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=277.337/29.017
=9.56

Mural Oncology's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=239.428/21.247
=11.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Mural Oncology Current Ratio Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines